NY-DILIGENT/GALVANIZE
24.2.2021 23:02:06 CET | Business Wire | Press release
Diligent Corporation (“Diligent” or the “Company”), the modern governance company with a platform used by nearly 700,000 board directors and leaders, across 19,000 clients, today announced that it has signed an agreement to acquire Galvanize, a global leader in SaaS governance, risk, and compliance (GRC) software. Financial terms of the transaction were not disclosed. The Galvanize transaction follows Diligent’s planned acquisition of Steele Compliance Solutions, Inc. (“Steele”) a leader in ethics and compliance SaaS, which the Company signed in February 2021. Both transactions are expected to close in March.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224006109/en/
With the acquisition of Galvanize, Diligent will become the largest SaaS GRC provider. The combined solution with enrichment from Steele will enable an integrated GRC picture – from Audit, Risk, Information Security, Ethics and Compliance across the organization directly to the CEO, CFO and Board. Customers will benefit from a powerful operating system that enables governance programs organization-wide, backed by trusted concierge level customer support with NPS scores over 50.
Galvanize, the only company with comprehensive “Leader” recognition from both Gartner and Forrester analysts, brings the only integrated cloud GRC platform powered by robotic data automation across security, risk management, compliance, and audit software for 6,000 global customers in 130 countries, including more than half of the Fortune 1000 and S&P 500. As a FedRAMP-authorized cloud service provider, Galvanize is trusted by more than 900 government agencies worldwide, including most large agencies in the U.S. federal government, to advance their missions transparently and efficiently.
Diligent plans to enhance its modern governance platform with Galvanize’s 11 integrated risk and compliance solutions, bringing new insights to its leading board and leadership application and operational governance solutions. Galvanize’s flagship cloud-based platform – HighBond – aggregates risk and compliance concerns to top-level strategy across the organization, with real-time dashboards of comprehensive business metrics to the C-Suite and Board.
“We are on the cusp of a new era. Executives and their boards are navigating incredible challenges and opportunities across all of their stakeholders. More than ever, they need an integrated view of data and information, as well as clear visibility and confidence for decision-making, to effectively maximize performance and mitigate risk,” said Brian Stafford, CEO of Diligent. “Risk and Compliance data traditionally sits in disparate systems across audit, compliance and risk functions and make it difficult and laborious to combine into one view for the CFO, CEO and Board. Together with Galvanize and Steele, we are excited to drive even greater impact for our clients through a completely integrated GRC platform so they can run more effective, equitable, sustainable, and successful organizations.”
Laurie Schultz, president & CEO of Galvanize said: “This transaction fast forwards our vision as the operating system of conscious organizations and furthers our mission to make GRC today’s mission-critical enterprise platform. Joining forces with Diligent, the clear market leader in the governance space, represents an immediate, material and meaningful redefinition of the $41 billion GRC market. With Diligent’s presence in thousands of boardrooms across the globe, our combined offering ensures all levels of an organization will have the real-time insight they need to manage risk and optimize performance.”
Credit Suisse served as the exclusive financial advisor, and Willkie Farr & Gallagher LLP served as the legal advisor to Diligent. For Galvanize, Evercore served as the financial advisor, and Fasken Martineau DuMoulin LLP served as the legal advisor.
About Diligent Corporation
Diligent powers modern governance, enabling transformational leaders to help their organizations do the right thing. Our governance platform provides new ways for leaders to digitally transform their governance practices, from increasing board and executive effectiveness to proactively managing risk and compliance practices to integrating real-time industry and company data like cyber risk scores and board composition. Diligent empowers leaders and teams to stay connected, informed, and ahead of what’s next so they can run more successful, equitable, and sustainable organizations – and create positive change in the world.
Today, nearly 700,000 governance leaders from over 19,000 organizations and 90 countries rely on the Diligent modern governance platform. With more than 1,000 employees globally, serving both public and private sectors, we are helping organizations digitize their governance practices and transform effective governance into a long-term, competitive advantage. Learn more at Diligent.com.
About Galvanize
Galvanize is the leading provider of award-winning, cloud-based security, risk management, compliance, and audit software for some of the world’s largest organizations. The integrated HighBond platform provides visibility into risk, makes it easy to demonstrate compliance, and helps grow audit, risk, and compliance programs without incurring extra costs. More than 6,000 organizations in 130 countries rely on HighBond to meet their objectives, including over half of the Fortune 1000 and S&P 500 companies, hundreds of banks, manufacturers, healthcare and government organizations. Whether managing threats, assessing risk, measuring controls, monitoring compliance, or expanding assurance coverage, HighBond automates manual tasks, blends organization-wide data, and broadcasts it in easy-to-share dashboards and reports. Learn more at WeGalvanize.com.
About Steele Compliance Solutions, Inc.
Steele is the global leader in Ethics & Compliance Management. We partner with the world’s largest, most respected companies to deliver compliance products and services that help organizations embrace a culture of compliance while protecting their brand. Learn more at SteeleGlobal.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210224006109/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom